Pfizer and Astellas' PADCEV + Keytruda Combo Shows Near 50% Reduction in Bladder Cancer Recurrence Risk
Event summary
- Pfizer and Astellas' Phase 3 EV-304 trial shows PADCEV + Keytruda reduces recurrence or death risk by 47% in cisplatin-eligible muscle-invasive bladder cancer patients.
- Two-year event-free survival rate at 79.4% for the combination therapy vs. 66.2% for standard neoadjuvant chemotherapy.
- Overall survival improved by 35% with the combination therapy compared to neoadjuvant chemotherapy.
- Data presented at the ASCO Genitourinary Cancers Symposium on February 27, 2026, with potential regulatory filings discussed.
The big picture
The EV-304 trial results mark a significant advancement in the treatment of muscle-invasive bladder cancer, potentially shifting the standard of care from platinum-based chemotherapy to targeted combination therapies. This development underscores the growing importance of antibody-drug conjugates and immune-oncology combinations in oncology. The collaboration between Pfizer, Astellas, and Merck highlights the strategic focus on leveraging complementary expertise to drive innovation in hard-to-treat cancers.
What we're watching
- Regulatory Approval
- Whether the positive EV-304 results will lead to regulatory approval for PADCEV + Keytruda in cisplatin-eligible MIBC patients, expanding its market potential.
- Market Competition
- How this combination therapy will position against existing and emerging treatments for muscle-invasive bladder cancer.
- Commercialization Strategy
- The pace at which Pfizer and Astellas can scale the commercialization of this combination therapy globally.
Related topics